Novo's New Insulin Reduces Risk of Low Blood Sugar, Study Shows

Novo Nordisk said its new insulin Tresiba carries about the same risk of serious heart problems as Sanofi ’s Lantus but offers significantly lower risk of dangerously low blood sugar in people with Type-2 diabetes.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: FREE Source Type: news